Humacyte shareholders approve 57% increase in authorized shares to 550M

Filed June 9, 2026 · Period ending June 9, 2026 · ~1 min read

Key Changes

• high

  Shareholders approved expanding authorized common stock from 350M to 550M shares, effective June 9, 2026. This gives management 200M additional shares for potential capital raises, acquisitions, or employee compensation, which could dilute existing holders.

  Item 5.07: Annual Meeting Results verify on EDGAR →
• medium

  Three Class II directors elected to serve until 2029: John Bamforth, Keith Jones, and Kathleen Sebelius. All received majority support with approximately 65M shares not voting due to broker non-votes.

  Item 5.07: Director Elections verify on EDGAR →
• medium

  Executive compensation approved on advisory basis with 67% support (40M for vs 19M against), suggesting some shareholder concern about pay levels. Shareholders also voted to hold this advisory vote annually going forward.

  Item 5.07: Say-on-Pay Vote verify on EDGAR →